title: Robotic-assisted transperitoneal aortic lymphadenectomy as part of staging procedure for gynaecological malignancies: single institution experience.
abstract: Introduction. This study was designed to confirm the feasibility and safety of robotic-assisted transperitoneal aortic lymphadenectomy as part of staging procedure for gynecologic malignancies. Methods. Chart review of 51 patients who had undergone robotic staging with aortic lymphadenectomy for different gynaecologic malignancies was performed. Results. The primary diagnosis was as follows: 6 cases of endometrial cancer, 31 epithelial ovarian cancer, 9 nonepithelial ovarian cancer, 4 tubal cancer, and 1 cervical cancer. Median BMI was 23 kg/m(2). Except for a single case of aortic lymphadenectomy only, both aortic and pelvic lymphadenectomies were performed at the time of the staging procedure. All the para-aortic lymphadenectomies were carried out to the level of the renal veinl but 6 cases were carried out to the level of the inferior mesenteric artery. Hysterectomy was performed in 24 patiens (47%). There was no conversion to LPT. The median console time was 285 (range 195-402) with a significant difference between patients who underwent hysterectomy and those who did not. The median estimated blood loss was 50 mL (range 20-200). The mean number of removed nodes was 29 ± 9.6. The mean number of pelvic nodes was 15 ± 7.6, whereas the mean number of para-aortic nodes was 14 ± 6.6. Conclusions. Robotic transperitoneal infrarenal aortic lymphadenectomy as part of staging procedure is feasible and can be safely performed. Additional trocars are needed when pelvic surgery is also performed.
authors: Department of Gynecology, Cervical Cancer Center, European Institute of Oncology, Milan 20141, Italy.
authors: V
authors: V
authors: Zanagnolo
authors: D
authors: D
authors: Rollo
authors: T
authors: T
authors: Tomaselli
authors: P G
authors: PG
authors: Rosenberg
authors: L
authors: L
authors: Bocciolone
authors: F
authors: F
authors: Landoni
authors: G
authors: G
authors: Aletti
authors: M
authors: M
authors: Peiretti
authors: F
authors: F
authors: Sanguineti
authors: A
authors: A
authors: Maggioni
references: Gynecol Oncol. 2012 Jun;125(3):546-51
references: 22387522
references: Gynecol Oncol. 2003 Oct;91(1):139-48
references: 14529674
references: Eur J Gynaecol Oncol. 2007;28(2):77-82
references: 17479665
references: Gynecol Oncol. 2004 Oct;95(1):52-61
references: 15385110
references: Gynecol Oncol. 2003 Jun;89(3):504-13
references: 12798719
references: Gynecol Oncol. 2008 Oct;111(1):41-5
references: 18694588
references: Am J Obstet Gynecol. 2012 Jun;206(6):513.e1-6
references: 22409959
references: Gynecol Oncol. 1998 Oct;71(1):19-28
references: 9784314
references: Gynecol Oncol. 2008 Dec;111(3):407-11
references: 18829091
references: Gynecol Oncol. 2008 Dec;111(3):412-7
references: 18834620
references: Gynecol Oncol. 2012 Feb;124(2):260-4
references: 22036203
references: Gynecol Oncol. 2007 May;105(2):409-13
references: 17275077
references: Eur J Gynaecol Oncol. 2011;32(5):476-80
references: 22053656
references: Gynecol Oncol. 2002 Apr;85(1):81-8
references: 11925124
references: J Obstet Gynaecol Res. 2012 Jan;38(1):1-8
references: 22136216
references: Eur J Obstet Gynecol Reprod Biol. 2009 Dec;147(2):226-9
references: 19786318
references: Gynecol Oncol. 2009 Aug;114(2):162-7
references: 19428096
references: Int J Gynecol Cancer. 2002 Jan-Feb;12(1):22-6
references: 11860532
references: Obstet Gynecol. 2009 Jul;114(1):16-21
references: 19546753
references: Int J Gynecol Cancer. 2012 Jan;22(1):76-81
references: 22134121
references: Gynecol Oncol. 2008 Nov;111(2 Suppl):S18-23
references: 18771796
references: Am J Obstet Gynecol. 2008 Oct;199(4):360.e1-9
references: 18928974
references: Am J Obstet Gynecol. 2011 Jun;204(6):551.e1-9
references: 21411053
references: Surg Endosc. 2012 Sep;26(9):2430-5
references: 22407151
references: Int J Gynecol Cancer. 2010 Jan;20(1):184-7
references: 20130521
references: Gynecol Oncol. 2008 Apr;109(1):11-8
references: 18304622